Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Regains Nasdaq Compliance

NEW YORK (GenomeWeb) – OpGen announced today that it has received notification from the Nasdaq that it has regained compliance with the market's applicable listing standards, and that its stock will continue to be listed and traded on the exchange.

OpGen was warned by the Nasdaq in June 2017 that its shares failed to maintain a minimum bid price of $1 per share for at least 30 consecutive trading days, and that it faced delisting. The company said at the time that it planned to undertake several actions to correct the deficiency.

It closed a $10 million public offering in July 2017, effected a 1-for-25 reverse stock split of its common shares in January 2018, and last week it priced another public stock offering with the aim of raising $12 million.

Now, the Nasdaq has informed OpGen that the minimum bid price deficiency of the firm's stock has been cured. The firm's scheduled hearing before a Nasdaq Hearings Panel, planned for Feb. 8, has been cancelled.

OpGen's shares were down about 5 percent to $2.82 in morning trading on the Nasdaq.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.